A global, randomized Phase 3 trial of ONZEALD (etirinotecan pegol) in patients with advanced breast cancer and brain metastases
Latest Information Update: 06 Jun 2016
At a glance
- Drugs Etirinotecan pegol (Primary)
- Indications Advanced breast cancer
- Focus Registrational; Therapeutic Use
- Sponsors Nektar Therapeutics
- 06 Jun 2016 New trial record
- 01 Jun 2016 According to a Nektar Therapeutics media release, this trial may serve as a potential registrational study for approval of Onzeald in the US. This trial is being performed to satisfy EMA's requirement for additional controlled data with the MAA for conditional approval.